Upcoming Biologics Events

Biologics UK: In-Person

21 - 22 March 2022 |

London, UK

21 - 22 March 2022

London, UK

+ Digital Day: 23 March 2022 | Online

Join leaders, experts and researchers, connecting global pharma, biotech and academia for high-level discussions on the latest innovations in biologics development.

Antibody Engineering: Online

27 June 2022 |

Online: BST (UTC+1)

27 June 2022

Online: BST (UTC+1)

An intensive 1-day meeting that delves into the latest in antibody engineering and antibody-based therapeutics & a meeting place for experts working within engineering, computational tools and antibody-based therapeutics.

Oligonucleotide Chemistry & Therapeutics Symposium

14 September 2022 |

Online: BST (UTC+1)

14 September 2022

Online: BST (UTC+1)

An intensive 1-day meeting that delves into the latest developments in oligonucleotide synthesis, chemistry, process & analytical development, and therapeutics

Vaccines Europe: In-Person

29 - 30 November 2022 |

Berlin, Germany

29 - 30 November 2022

Berlin, Germany

Bringing together like-minded experts for topical discussions pertaining to vaccines, vaccine research & platform technologies

Upcoming Discussion Groups

Our monthly Discussion Groups are hosted by a panel of leading industry experts who explore some of the key issues facing biologics therapeutics today.

Register below to receive a live stream of the discussion as well a complimentary report outlining the key findings and conclusions covered.

Bi-and Multi-Specific Antibodies – Formats, Applications, and Paths to the Clinic

08 December 2021 | 14:00 GMT (09:00 EST)

Recent market demands for bispecific antibodies can largely be attributed to the application of existing commercially available products to other multiple indications. Currently, there are 2 bispecific antibodies commercially available on the market and over 200 in clinical trials. The future for the research and development of bispecific and multi-specific antibodies remains highly progressive and profitable, driven by the fact that an increasing number of big and small pharmaceutical companies are allocating their resources and are collaborating with other stakeholders of the industry. Challenges remain, however, and in our next biologics discussion group we bring together an exclusive panel of key opinion leaders to discuss the key factors behind the market’s growth, priorities, future outlook & challenges.

Panel Discussion: Bi-and Multi-Specific Antibodies – Formats, Applications, and Paths to the Clinic

  • Cell engager activities 
  • Choice of format and characteristics
        » Geometry 
        » Valency
        » Affinity 
        » Ability to high-throughput screening 
  • Bispecific portfolios & recent approvals 
  • Bispecifics outside oncology: infectious diseases, autoimmunity  
  • Manufactruing and FDA approval
        » Solutions to manufacturing issues 
        » Pathways for approval

     

Discussion Group Leaders

  • William Olson, Senior Vice President, Regeneron
  • Jonathan Davis, Vice President of Innovation and Strategy, Invenra 

Reports and write-ups pertaining to previous Discussion Groups are available in our Insights section.

Previous Discussion Groups

Biotherapeutics representing an exciting class of modalities have been gaining renewed attention over the past few years, though challenges still remain. Their analytical development is one area with a lot of promise thanks to new platforms and softwares available. In addition to this, there are advancements pertaining to their characterisation and using of AI/ML. This live session brings together experts to look at the latest developments in the field for an hour of a discussion on automation, instrumentation, real-time release testing, and novel technologies.

Panel Discussion: Analytical Development for Diverse Modalities

  • Analytical method development for protein therapeutics and other biologics 
  • Novel analytical methods  
  • Mass spec-based assay development  
  • Automation
  • Characterisation  
  • Instrumentation 
  • Real-time release testing  
  • Novel technologies, digital transformation

Moderator: Amy Than, Senior Principal Scientist, Pfizer

Panellists:

  • Rachel Chen, Senior Scientist, Analytical Development, Biogen  
  • Galahad Deperalta, Senior Scientist, Genentech

With the recent advancements of antibody engineering technologies, techniques and methods, the market has seen an expansion. This growth is largely attributed to our better understanding of new modalities, smarter ways of choosing our targets and ensuring their quality, though challenges still remain. Our September discussion groups brings together an exclusive panel of key opinion leaders discussing the key factors behind the market’s growth, its priorities, future outlook & challenges.

Presentation: Antibody Discovery At Novo Nordisk

  • Complementary technical approaches
  • Current initiatives to develop better antibodies faster

Speaker: Erik Vernet, Director, Antibody technology, Novo Nordisk

Panel Discussion: Oral Delivery of Biologics – Current Challenges & Opportunities

  • Discovery strategy: in vivo and in vitro
  • Multi parameter developability
  • Display technologies – what are the current trends in the industry?
  • Incorporating ML/AI into the discovery pipeline
  • Hybridoma platform – Does it still have its place?

Moderator: Erik Vernet, Director, Antibody Technology, Novo Nordisk

Panellists:

  • William Olson, Senior Vice President, Therapeutic Peptides, Regeneron
  • Rick Davies, Senior Director of Chemical Biology and Protein Science, AstraZeneca
  • Jonathan Davis, Vice President of Innovation & Strategy, Invenra 

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Download Series Agenda at a Glance

Submit your details to register your interest & to be kept up to date about relevant services or events. You may opt-out at any time. Please check our Privacy Policy to see how Oxford Global protects and manages your data.

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Biologics

Submit your details to receive the monthly newsletter & to be kept up to date about relevant events, monthly discussion groups and portal membership offers. You may opt-out at any time. Please check our Privacy Policy to see how Oxford Global protects and manages your data.